Targets › F2
19 programs from 18 companies in 26 trials: 13 Phase 4, 6 Phase 2, 4 Phase 3, 3 Phase 1; Cardiovascular, Hematology, Other; next expected readout Dec 2026.
Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C. Functions in blood homeostasis, inflammation and wound healing. Activates coagulation factor XI (F11); activation is promoted by the contact with negatively charged surfaces. (UniProt, P00734)
Open in Phaseline: the race on F2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Medical University of Vienna | Argatroban Thrombin inhibitor | F2 | Phase 4 | Respiratory Insufficiency | Jan 2027 |
| Herlev and Gentofte Hospital | Dabigatran Etexilate Thrombin inhibitor | F2 | Phase 4 | Deep Vein Thrombosis; Atrial Fibrillation | Mar 2027 |
| Population Health Research Institute | Dabigatran Thrombin inhibitor | F2 | Phase 4 | Stroke; Bleeding Post Cardiac Surgery | Jun 2027 |
| Imperial College London | Dabigatran Etexilate Thrombin inhibitor | F2 | Phase 4 | Venous Thromboembolism | Jun 2027 |
| The University of Hong Kong | Dabigatran etexilate Thrombin inhibitor | F2 | Phase 4 | Atrial Fibrillation | Sep 2027 |
| McGill University Health Centre/Research Institute of the McGill University Health Centre | Dabigatran Thrombin inhibitor | F2 | Phase 4 | Staphylococcus Aureus Endocarditis | Jan 2030 |
| Peking University First Hospital | Bivalirudin Thrombin inhibitor | F2 | Phase 4 | Coronary Microvascular Dysfunction | – |
| Medical University of Gdansk | Dabigatran Etexilate Thrombin inhibitor | F2 | Phase 4 | Atrial Fibrillation | – |
| Children's Hospital Los Angeles | Feiba Activated prothrombin complex concentrate (aPCC) - contains vitamin K-dependent clotting f | F2, F7, F10 | Phase 4 | Hemophilia A With Inhibitor | – |
| CSL Behring | Prothrombin Complex Concentrate (BE1116) Coagulation factor VII exogenous protein; Vitamin K-dependent protein S exogenous protein; Vitamin K-dependent protein C exogenous protein | F7, PROS1, PROC, F9, F2 | Phase 3 | Complex Cardiovascular Surgery With Cardiopulmonary Bypass; Cardiac Valve Disease; Hemophilia; Liver Cirrhosis | Apr 2027 |
| Icahn School of Medicine at Mount Sinai | Dabigatran Thrombin inhibitor | F2 | Phase 3 | Atrial Fibrillation | – |
| Icahn School of Medicine at Mount Sinai | Oral Anticoagulant (OAC) - Vitamin K Antagonist (VKA) or Direct Oral Anticoagula Vitamin K antagonist or factor Xa/IIa inhibitor anticoagulation | F2, F7, F9, F10 | Phase 3 | Atrial Fibrillation | – |
| New York Medical College | Defibrotide Adenosine A2 receptor agonist; Plasminogen activator; Adenosine A1 receptor agonist | ADORA2B, ADORA2A, PLG, ADORA1, F2 | Phase 2 | Sickle Cell Disease; Sinusoidal Obstruction Syndrome | Dec 2026 |
| Zhujiang Hospital | Nafamostat Mesilate Serine protease inhibitor; anticoagulant | F2, F2R, PLAU | Phase 2 | Continuous Renal Replacement Therapy (CRRT) | Mar 2027 |
| Stanford University | Bivalirudin Thrombin inhibitor | F2 | Phase 2 | Heart Failure | Sep 2027 |
| Northwell Health | FEIBA Factor VIII inhibitor bypass activity - prothrombin complex concentrate containing factors | F2, F7, F9, F10 | Phase 2 | Cardiac Disease | Nov 2028 |
| Sydney Local Health District | Bivalirudin Thrombin inhibitor | F2 | Phase 2 | Extracorporeal Membrane Oxygenation Complication | – |
| Bayer | BAY3389934 Factor IIa (thrombin) and Factor Xa inhibitor | F2, F10 | Phase 1 | Sepsis; Drug-drug Interaction | Dec 2026 |
| Shaanxi Micot Pharmaceutical Technology | MT1011 Factor IIa and Factor Xa inhibitor reversal agent | F2, F10 | Phase 1 | Used in Patients Receiving Anticoagulant Therapy (e.g., Rivaroxaban or Apixaban, Inhibitors of Coagulation Factor Xa) Who Require Reversal of Anticoagulation | – |
Atrial Fibrillation (5) Staphylococcus Aureus Endocarditis (1) Deep Vein Thrombosis (1) Heart Failure (1) Venous Thromboembolism (1) Sickle Cell Disease (1) Sinusoidal Obstruction Syndrome (1) Stroke (1) Bleeding Post Cardiac Surgery (1) Sepsis (1) Drug-drug Interaction (1) Respiratory Insufficiency (1)
small molecule (17), protein or peptide (2)
Icahn School of Medicine at Mount Sinai (2) McGill University Health Centre/Research Institute of the McGill University Health Centre (1) Herlev and Gentofte Hospital (1) Stanford University (1) Imperial College London (1) New York Medical College (1) Population Health Research Institute (1) Medical University of Gdansk (1) Bayer (1) Medical University of Vienna (1) Northwell Health (1) The University of Hong Kong (1) Shaanxi Micot Pharmaceutical Technology (1) Sydney Local Health District (1) Peking University First Hospital (1) CSL Behring (1) Children's Hospital Los Angeles (1) Zhujiang Hospital (1)
F10 (5) F7 (4) F9 (3) ADORA2B (1) ADORA2A (1) PLG (1) ADORA1 (1) PROS1 (1) PROC (1) F2R (1) PLAU (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.